US20190275071A1 - Particle-mediated delivery of biologics - Google Patents

Particle-mediated delivery of biologics Download PDF

Info

Publication number
US20190275071A1
US20190275071A1 US16/463,053 US201716463053A US2019275071A1 US 20190275071 A1 US20190275071 A1 US 20190275071A1 US 201716463053 A US201716463053 A US 201716463053A US 2019275071 A1 US2019275071 A1 US 2019275071A1
Authority
US
United States
Prior art keywords
particle
mir
mrna
alginate
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/463,053
Other languages
English (en)
Inventor
Atta Behfar
Andre Terzic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Priority to US16/463,053 priority Critical patent/US20190275071A1/en
Assigned to MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH reassignment MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEHAR, ATTA, TERZIC, ANDRE
Publication of US20190275071A1 publication Critical patent/US20190275071A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
US16/463,053 2016-11-23 2017-11-22 Particle-mediated delivery of biologics Abandoned US20190275071A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/463,053 US20190275071A1 (en) 2016-11-23 2017-11-22 Particle-mediated delivery of biologics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662426090P 2016-11-23 2016-11-23
US16/463,053 US20190275071A1 (en) 2016-11-23 2017-11-22 Particle-mediated delivery of biologics
PCT/US2017/063060 WO2018098312A2 (en) 2016-11-23 2017-11-22 Particle-mediated delivery of biologics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/063060 A-371-Of-International WO2018098312A2 (en) 2016-11-23 2017-11-22 Particle-mediated delivery of biologics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/567,482 Continuation US20220152084A1 (en) 2016-11-23 2022-01-03 Particle-mediated delivery of biologics

Publications (1)

Publication Number Publication Date
US20190275071A1 true US20190275071A1 (en) 2019-09-12

Family

ID=62195620

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/463,053 Abandoned US20190275071A1 (en) 2016-11-23 2017-11-22 Particle-mediated delivery of biologics
US17/567,482 Pending US20220152084A1 (en) 2016-11-23 2022-01-03 Particle-mediated delivery of biologics

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/567,482 Pending US20220152084A1 (en) 2016-11-23 2022-01-03 Particle-mediated delivery of biologics

Country Status (6)

Country Link
US (2) US20190275071A1 (de)
EP (2) EP3973955A3 (de)
JP (2) JP7121005B2 (de)
CA (1) CA3044703A1 (de)
ES (1) ES2912270T3 (de)
WO (1) WO2018098312A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3796944A4 (de) * 2018-05-23 2022-04-06 Mayo Foundation for Medical Education and Research Mikroverkapselte modifizierte polynukleotidzusammensetzungen und verfahren
CN108753726B (zh) * 2018-06-11 2020-10-09 西南医科大学 一种含有ECRG4 mRNA的外泌体及其制备方法和应用
WO2021184020A1 (en) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
CN114984184A (zh) * 2021-03-02 2022-09-02 上海交通大学医学院附属上海儿童医学中心 增强tbx1表达在修复心脏组织损伤中的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
EP2292771A3 (de) * 1997-09-19 2011-07-27 Life Technologies Corporation Sense mRNA Therapie
AU2006306228A1 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
KR101095943B1 (ko) 2006-02-21 2011-12-19 밀리켈빈 테크놀로지스 엘엘씨 과분극화 방법, 시스템 및 조성물
EP2125030A2 (de) * 2007-01-29 2009-12-02 Medipol S.A. Kolloidale partikel auf chitosan-basis zur rna-abgabe
US9822364B2 (en) * 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9241898B2 (en) * 2008-03-11 2016-01-26 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
PT2506857T (pt) * 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
EP2600901B1 (de) * 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
SG193615A1 (en) 2011-03-29 2013-11-29 Beta Cell Nv Method for encapsulated therapeutic products and uses thereof
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP4074834A1 (de) 2012-11-26 2022-10-19 ModernaTX, Inc. Am kettenende modifizierte rna
EP2929035A1 (de) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidnanopartikel zur freisetzung von mrna
ES2767050T3 (es) 2013-09-03 2020-06-16 Mayo Found Medical Education & Res Reducción del riesgo de eventos cardíacos adversos mayores
EP4276176A3 (de) * 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna-therapie für argininosuccinat-synthase-mangel
NZ718817A (en) 2013-10-22 2020-07-31 Massachusetts Inst Technology Lipid formulations for delivery of messenger rna
ES2774552T3 (es) * 2014-03-24 2020-07-21 Translate Bio Inc Terapia de ARNm para el tratamiento de enfermedades oculares
RU2718590C2 (ru) 2014-11-10 2020-04-08 Этрис Гмбх Индукция остеогенеза путем внедрения рнк, кодирующей костный морфогенетический белок (кмб)
EP3796944A4 (de) * 2018-05-23 2022-04-06 Mayo Foundation for Medical Education and Research Mikroverkapselte modifizierte polynukleotidzusammensetzungen und verfahren

Also Published As

Publication number Publication date
CA3044703A1 (en) 2018-05-31
EP3544591B1 (de) 2022-04-20
JP2020500857A (ja) 2020-01-16
EP3544591A2 (de) 2019-10-02
JP2022140640A (ja) 2022-09-26
JP7469397B2 (ja) 2024-04-16
WO2018098312A3 (en) 2018-07-05
EP3973955A3 (de) 2022-06-15
EP3544591A4 (de) 2020-10-07
WO2018098312A2 (en) 2018-05-31
US20220152084A1 (en) 2022-05-19
ES2912270T3 (es) 2022-05-25
EP3973955A2 (de) 2022-03-30
JP7121005B2 (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
US20220152084A1 (en) Particle-mediated delivery of biologics
Zhang et al. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
CN107427466B (zh) 从细胞膜衍生的纳米囊泡及其用途
US20180296483A1 (en) Microvesicles derived from nucleated, mammalian cells and use thereof
JP2022542389A (ja) 拘束された脂質を含むナノ材料およびその使用
CN108451929B (zh) 一种包载固相内核的重组脂蛋白及其制备和应用
WO2021031839A1 (zh) 一种靶向多肽修饰的载药脂蛋白纳米递药系统及其制备和应用
Hadjizadeh et al. Polymeric scaffold based gene delivery strategies to improve angiogenesis in tissue engineering: a review
Hahm et al. Strategies to enhance extracellular vesicle production
Pofali et al. Exosome as a natural gene delivery vector for cancer treatment
CN107867677B (zh) 一维磷酸钙纳米/微米材料及其制备方法和应用
US20210205229A1 (en) Microencapsulated modified polynucleotide compositions and methods
CN115029310B (zh) 一种破骨前体细胞膜仿生纳米颗粒及制备方法和应用
US20220031633A1 (en) Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
Prosen et al. Magnetofection: an effective, selective and feasible non-viral gene delivery method
Song et al. Efficient Delivery of Lomitapide Using Hybrid Membrane‐Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy
Faria Internship Reports and Monograph entitled" Stem Cell Membrane-Coated Nanosystems for Biomedical Applications"
Jhunjhunwala Nucleic Acid Nanotherapeutics
Zhang et al. Charge‐Reversed Exosomes for Targeted Gene Delivery to Cartilage for Osteoarthritis Treatment
Siddiqui et al. Application of Nanomaterials in Cancer Diagnosis, Drug Delivery, and Therapy
Raso et al. Non-coding RNA Research
EP3886911A1 (de) Biomembranbeschichtete nanopartikel (bionps) zur abgabe von wirkstoffen an stammzellen

Legal Events

Date Code Title Description
AS Assignment

Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEHAR, ATTA;TERZIC, ANDRE;REEL/FRAME:049534/0359

Effective date: 20190520

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION